Dr. Antonio Garrido Montalban

Dr. Antonio Garrido Montalban has over 25 years of experience in the pharmaceutical industry. Dr. Antonio began their career in 1995 as a Postdoctoral Research Fellow at Imperial College London, where they worked with Professor Anthony G.M. Barrett in collaboration with Professor Brian M. Stoltz. In 1998, they became an Assistant Professor in the Department of Chemistry at Imperial College London, where they taught undergraduate laboratory classes. In 2002, they joined Kemia Inc. as a Senior Scientist II, working on the design and synthesis of HIV entry inhibitors. Dr. Antonio was quickly promoted to Senior Scientist I and Senior Scientist II, and was given the medicinal chemistry project leadership of Kemia's P38 program. In 2008, they joined Arena Pharmaceuticals as the Senior Director and Head of Chemical R&D, and was later promoted to Director and Head of Chemical R&D, Head of Pilot Plant and GMP Operations, and Associate Director of Chemical R&D. In 2016, they became the Executive Director and Site Head at STA Pharmaceutical, a WuXi AppTec Company (WuXi STA). Most recently, in 2019, they joined Arena Pharmaceuticals, Inc./Pfizer Inc. as the Head of Early Stage Drug Substance Development. In 2022, they will become the Vice President of Drug Substance at BlossomHill Therapeutics, Inc.

Dr. Antonio Garrido Montalban has an extensive education history. In 1983, they attended Paul Ehrlich School and earned a Chemielaborant and High School Diploma in Chemistry. From 1987 to 1991, they attended Darmstadt University of Applied Sciences, where they earned a Chemical Engineer degree in Chemical Technology. Finally, from 1991 to 1995, they attended University of East Anglia, where they earned an MSc and PhD in Synthetic Organic Chemistry.